December 8, 2020
by Sonendo, Inc.
Sonendo, Inc., a leading dental technology company and developer of the GentleWave® System, today announced that more than 500,000 patients have been treated with the GentleWave Procedure.
Sonendo’s GentleWave System ushers in the next evolution in endodontic technology that is transforming a rapidly growing number of practices across North America. The GentleWave System uses patented, novel technology to deliver more thorough cleaning and disinfection to the entire root canal system —even in the microscopic places where bacteria can hide—and leaves more of the tooth structure intact1,2.
Most GentleWave Procedures can be performed in one visit3 and in general, patients find the procedure to be comfortable and report minimal to no pain after the procedure4. Additionally, the System releases virtually no aerosolized material into the air during normal use5, which potentially reduces the threat of spread of airborne infection – such as COVID-19 – to patients, clinicians, and their staff. Procedure instruments for the GentleWave System also come pre-sterilized and are single use, hence minimize the risk of exposure from one patient to the next.
Bjarne Bergheim, Sonendo’s President & CEO, reflected on the significance of this milestone. “We are grateful to the many clinicians and their staff who have supported us on this journey that has now positively impacted the lives of more than 500,000 patients.
Our innovation is always centered around the patient and it is very humbling to see the strong adoption. This landmark achievement underscores the market demand for GentleWave Procedures and further demonstrates our commitment to partner with endodontists to advance and elevate patient care.
We are also very thankful to all the employees and their families who remain steadfast in their commitment to making a difference in the lives of people and helped us reach this milestone.”
Patients interested in learning more about the GentleWave Procedure, the alternative to traditional root canal treatment, or to find providers can visit www.GentleWave.com.
Sonendo, Inc. is a privately held company developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment6,7,8. Sonendo is the parent company of TDO® Software, the developer of the most widely used endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.
For more information about Sonendo visit www.sonendo.com. For information about TDO visit www.tdo4endo.com
1Vandrangi P et al. (2015) Oral Health 72-86 2Molina B et al. (2015) J Endod. 41:1701-05 3 Sigurdsson et al. J Endod 2018; 44(3):510-517 4Sigurdsson et al. J Endod 2016; 41(7):1040-10484 5Data on file at Sonendo; internal testing report# TR20-002 6Sigurdsson A et al. (2016) J Endod. 42:1040-48 7Molina B et al. (2015) J Endod. 41:1701-05 8Trope M et al. (1999) J Endod. 25:345–50
This announcement contains forward-looking statements based on management’s beliefs, assumptions and expectations and information currently available to management. All statements that address events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations on the timing and progress of research and development activities. Management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on forward-looking statements because they speak only as of the date when made. Sonendo does not assume any obligation to update or revise any forward-looking statements publicly, whether as a result of new information, future events or otherwise. Actual results, developments, or events could differ materially from those disclosed in the forward-looking statements.
Your email address will not be published. Required fields are marked *
Save my name, email, and website in this browser for the next time I comment.
read more >>